Belpointe Asset Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.33M Hold
5,688
– – 0.04% 442
2026
Q2
$1.21M Buy
+5,688
New +$1.12M 0.04% 435
2023
Q2
– Sell
-1,850
Closed -$262K – 1241
2023
Q1
$262K Buy
1,850
+377
+26% +$53.9K 0.01% 812
2022
Q4
$230K Buy
1,473
+81
+6% +$11.6K 0.01% 834
2022
Q3
$171K Buy
1,392
+94
+7% +$12.4K 0.01% 905
2022
Q2
$172K Sell
1,298
-524
-29% -$71.4K 0.01% 886
2022
Q1
$249K Sell
1,822
-4,016
-69% -$560K 0.02% 809
2021
Q4
$1.01M Buy
5,838
+4,250
+268% +$647K 0.06% 315
2021
Q3
$231K Hold
1,588
– – 0.02% 802
2021
Q2
$209K Sell
1,588
-220
-12% -$28.8K 0.02% 821
2021
Q1
$232K Sell
1,808
-226
-11% -$27.8K 0.02% 695
2020
Q4
$243K Sell
2,034
-4,139
-67% -$505K 0.02% 633
2020
Q3
$706K Buy
6,173
+342
+6% +$40.4K 0.08% 261
2020
Q2
$664K Buy
5,831
+3,861
+196% +$410K 0.09% 240
2020
Q1
$158K Buy
+1,970
New +$204K 0.03% 479
2019
Q2
– Sell
-1,235
Closed -$111K – 620
2019
Q1
$111K Buy
+1,235
New +$107K 0.02% 424
2018
Q4
– Sell
-1,157
Closed -$125K – 526
2018
Q3
$125K Buy
+1,157
New +$127K 0.02% 581

Other funds holding DGX

Belpointe Asset Management's DGX Position: Q3 2026 in Review

Belpointe Asset Management held its Quest Diagnostics (DGX) position steady in Q3 2026 at 5,688 shares worth $1.33M. The position accounts for 0.04% of the portfolio, ranked #442.

Belpointe Asset Management first reported a position in DGX in Q3 2018 and has held it in 17 quarters since. 978 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Belpointe Asset Management held 5,688 shares of Quest Diagnostics worth $1.33M as of Q3 2026.
  • Belpointe Asset Management left its Quest Diagnostics share count unchanged in Q3 2026.
  • Quest Diagnostics made up 0.04% of Belpointe Asset Management's portfolio in Q3 2026, its #442 holding.
  • Belpointe Asset Management first reported a position in Quest Diagnostics in Q3 2018 and has held it in 17 quarters since.
  • 978 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Belpointe Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.